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Abstract 
Globally, the number of older adults is increasing at a rapid pace. The number of people 
aged 65 and older is projected to grow from an estimated 524 million in 2010 to nearly 
1.5 billion in 2050 [1, 2]. Consequently, urological cancers such as prostate cancer (PCa) 
and urothelial cancer have been increasing, and these cancers are one of the most common 
cancers in the world. Moreover, the approach to urological cancer treatment has huge 
impact on patient’s health-related quality of life (HRQOL), however, the approach to 
urological cancer treatment is by no means satisfactory, and new progress has been 
required. In this study, I performed pharmacological studies on causal factors and 
pharmacological therapies for urological cancer in order to satisfy this unmet medical 
needs (UMN). 
In the first chapter, I described the biochemical and cell biological analysis of aldo-
keto reductase family 1 member C3 (AKR1C3) inhibitor ASP9521 that is a therapeutic 
agent for PCa. ASP9521 inhibited conversion of androstenedione (AD) into testosterone 
(T) potently by recombinant human or cynomolgus monkey AKR1C3 in a concentration-
dependent manner. ASP9521 showed >100-fold selectivity for AKR1C3 over the isoform 
AKR1C2. In LNCaP-AKR1C3 cells stably expressing human AKR1C3, ASP9521 
suppressed AD-dependent prostate specific antigen (PSA) production and cell 
proliferation. In CWR22R xenografts, single oral administration of ASP9521 (3 mg/kg) 
inhibited AD-induced intratumoral T production and this inhibitory effect was maintained 
for 24 h. Based on these findings I discussed the physiological role of AKR1C3 in PCa 
androgen metabolism. 
In the second chapter, I described the inhibitory mechanism of a selective fibroblast 
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growth factor receptor (FGFR) inhibitor ASP5878, targeting FGFR3-fusion or -mutation 
positive urothelial cancer. ASP5878 showed potent anti-proliferative and antitumor 
activity in urothelial cancer cell line harboring FGFR3-transforming acid coiled coil 3 
(TACC3), FGFR3-BAI1-associated protein 2-like 1 (BAIAP2L1) or FGFR3 point 
mutation and their tumor xenografted models. This anti-proliferative activity is based on 
inhibitory effects of FGFR3 phosphorylation and extracellular signal-regulated kinase 
(ERK) phosphorylation, a downstream signaling molecule in these urothelial cancer cell 
lines harboring FGFR3 gene alternations. Additionally, I established chemotherapy-
resistant cell lines: adriamycin-resistant UM-UC-14 and gemcitabine-resistant RT-112. 
ASP5878 also inhibited the proliferation of these cell lines. These findings suggest that 
ASP5878 has therapeutic potential against urothelial cancer harboring FGFR3-TACC3, 
FGFR3-BAIAP2L1 or FGFR3 point mutation even after the acquisition of gemcitabine- 
or adriamycin- resistance. 
On the basis of two studies, I propose that AKR1C3 inhibitor against PCa and FGFR3 
inhibitor against urothelial cancer harboring FGFR3-TACC3, FGFR3-BAIAP2L1 or 
FGFR3 point mutation can lead to a novel therapeutic approach for these urological 
cancers. I believe these studies can contribute to developing new therapeutic agent of 
urological cancer. 
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Abbreviations 
17βHSD5 17β-hydroxysteroid dehydrogenase type 5 
95% CI  95% confidential interval 
AA  abiraterone acetate 
AD  androstenedione 
ADT  androgen deprivation therapy 
AKT  protein kinase B 
AKR1C3 aldo-keto reductase family 1 member C3 
AR  androgen receptor 
BAIAP2L1 BAI1-associated protein 2-like 1 
BG  background 
DHEA   dehydroepiandrosterone 
DHT  dihydrotestosterone 
DMSO  dimethyl sulfoxide 
ERK  extracellular signal-regulated kinase 
FBS  fetal bovine serum 
FDA  Food and Drug Administration 
FGF  fibroblast growth factor  
FGFR  fibroblast growth factor receptor 
GC  gemcitabine/cisplatin 
HRQOL health-related quality of life 
IC50  50% inhibitory concentration 
LH-RH  luteinizing hormone releasing hormone 
MAPK  mitogen-activated protein kinase 
mCRPC  metastatic castration-resistant prostate cancer 
MDR1  multidrug-resistant transporter 1 
MIBC  muscle-invasive bladder cancer 
MVAC  methotrexate/vinblastine/adriamycin/cisplatin 
NADP  nicotinamide adenine dinucleotide phosphate 
NMIBC  non- muscle-invasive bladder cancer 
PBS  phosphate-buffered saline  
PAGE  polyacrylamide gel electrophoresis 
PCa  prostate cancer 
PI3K  phosphatidylinositol-4,5-bisphosphate 3-kinase 
PSA  prostate specific antigen 
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Ras  rat sarcoma 
SDS  sodium dodecyl sulfate 
STAT  signal transducer and activator of transcription 
T  testosterone 
TACC3  transforming acid coiled coil 3 
UMN  unmet medical needs 
WHO  World Health Organization 
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General Introduction 
According to World Health Organization (WHO), cancer is one of the leading causes 
of morbidity and mortality worldwide, with approximately 14 million new cases in 2012 
[3]. The number of new cases is expected to rise by about 70% over the next 2 decades. 
Cancer is the second leading cause of death in the world, and was responsible for 8.8 
million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer.  
Urological cancers, which consist of PCa, urothelial cancer, and renal cell cancer are 
common malignancies with increasing incidence and mortality worldwide. According to 
the most recent cancer statistics, urological cancers are major causes of morbidity and 
mortality: The American Cancer Society estimates that 318,980 new instances of 
urological cancer will be diagnosed and that 59,690 deaths will occur from urological 
cancers in 2017 in the USA [4]. I particularly focused on PCa and urothelial cancer 
because of these high UMN. 
PCa is the most common cancer in males, with a projected 161,360 new cases and 
26,730 deaths estimated in the USA in 2017 [4]. PCa cells usually require androgen 
hormones, such as T, to grow, therefore, a common treatment option for PCa is to lower 
the levels of androgen hormones in male body. Androgen signaling plays a pivotal role 
in the proliferation of PCa, and androgen deprivation therapy (ADT) is the standard 
treatment. ADT can be achieved either by surgical castration through bilateral 
orchiectomy or medical castration through the use of luteinizing hormone-releasing 
hormone (LH-RH) agonists or antagonists, which is the mainstay for treatment in PCa [5-
7]. ADT elicits a response in majority of patients with PCa. However, some patients will 
have recurrence of their disease after treatment and will progress to the castration-
resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC) over time. CRPC can be 
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defined as either progressively rising levels of serum tumor marker prostate-specific 
antigen (PSA) or detection of new or progressive metastatic tumors by radiographic scans, 
despite castrate T levels (below 50 ng/dL and recently updated to less than 20 ng/dL [8-
10]). Progression of disease in patients with mCRPC can lead to development of 
worsening symptoms and patients may experience decline in their HRQOL with ensuing 
increased pain [11-13]. mCRPC remains driven by the androgen axis, and despite the use 
of ADT, most patients with metastatic PCa will progress to CRPC, which still depends 
on androgen synthesis and androgen receptor (AR) signaling for proliferation. In addition, 
increased intratumoral production of androgens is also thought to result from upregulation 
of androgen biosynthesis enzymes. Two hormonal therapy agents, abiraterone acetate 
(AA) which inhibits androgen biosynthesis and enzalutamide which interferes with 
androgen-receptor signaling, have been approved in many countries, and have proven to 
be effective in the treatment of mCRPC (Figure 1) [14-18]. Unfortunately, many patients 
treated with these two agents will fail to respond to initial treatment with these drugs [14-
17]. Furthermore, within 24 months of initiating treatment, even those who initially 
respond to these drugs will develop resistance, therefore new methods by which treatment 
resistance develops in PCa are constantly identified. 
One of the key enzymes involved in adrenal and de novo intratumoral steroidal 
biosynthesis is AKR1C3, also called 17β-hydroxysteroid dehydrogenase type 5 
(17βHSD5). This enzyme plays a crucial role in the synthesis of dihydrotestosterone 
(DHT), by catalysing the conversion of the adrenal androgens dehydroepiandrosterone 
(DHEA), AD and 5α-androstanedione into DHT [19]. AKR1C3 is highly expressed in 
PCa cells [20-23], and its expression increases with increasing tumor aggressiveness [24], 
as demonstrated by upregulated AKR1C3 levels in patients with CRPC compared with 
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benign prostate and early stage PCa [25-31]. This is one of the reasons why AKR1C3 has 
been implicated in CRPC progression. 
 
Figure.1 hormonal therapy agents 
 
Urothelial carcinoma of the bladder cancer is the fourth most common cancer in males 
and the 11th most common in females, with a projected 79,030 new cases and 16,870 
deaths estimated in the USA in 2017. The incidence and death rate is approximately four 
times higher in males than females [4]. Urothelial cancer can arise anywhere along the 
epithelial lining of urinary tract, including the bladder, renal pelvis and ureter. Although 
urothelial cancers arising in these various locations have similar morphology and gene 
expression profile [32], urothelial cancer occurs most frequently in the bladder. Bladder 
cancer is mainly divided into two groups by stage. The stage classification differentiates 
between non-muscle-invasive and muscle-invasive tumors according to the depth of 
invasion. Non- muscle-invasive bladder cancers (NMIBC) highly recur, and at least 50% 
of patients will have recurring tumors. More than 60% of patients with the disease recur 
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within 4 months after surgery. For patients with unresectable or muscle-invasive bladder 
cancer (MIBC), first-line treatment with platinum-containing chemotherapy is considered 
the best available treatment option. Most efficacious are cisplatin-containing 
chemotherapy regimens, specifically cisplatin-gemcitabine (GC) and the combination of 
methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). While these treatments 
have demonstrated anti-tumor activity among this population, cisplatin-containing 
chemotherapies are associated with significant toxicities, and for this reason, nearly half 
of patients are ineligible to receive them [33]. Moreover, despite reasonable response rates 
to chemotherapy in patients with locally advanced or metastatic bladder cancer, long-term 
progression-free survival rates remain insufficient, [34] which is thought to be caused by 
the induction of multidrug-resistant transporter 1 (MDR1) overexpression or the 
alterations in the apoptotic machinery including overexpression of c-MYC, an 
oncoprotein [35, 36].  
FGFR3 is a member of a structurally related family of tyrosine kinase receptors 
(FGFR1–4) that regulate a variety of cellular activities, including proliferation, 
differentiation, and survival. Ligand binding promotes receptor dimerization, 
transphosphorylation of key tyrosine residues, and recruitment of adaptor proteins, 
ultimately leading to the activation of multiple downstream signaling cascades, including 
PI3K/AKT, RAS/MAPK, STATs, and phospholipase Cγ [37]. Point mutations of the 
FGFR3 gene such as S249C, Y375C, and K652E are one of the most frequent genetic 
alterations seen in bladder cancer, occurring in around 75% of all cases of NMIBC [38, 
39]. Recently, it has been also reported that FGFR3-TACC3 and FGFR3-BAIAP2L1 
fusion genes were identified in some urothelial cancer cell lines and cancer tissue samples 
[40, 41] Both FGFR3-TACC3 and FGFR3-BAI1AP2L1 translocations generate 
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constitutively activated and oncogenic FGFR3 kinase protein products, and cellular 
dependence on these drivers confers sensitivity to selective FGFR inhibition [40, 42]. In 
light of these considerations, FGFR3 has long been considered an attractive actionable 
target for novel therapeutic approaches in urothelial bladder cancer [43]. 
Based on these two studies, I propose that AKR1C3 inhibitor and FGFR3 inhibitor can 
lead to a novel and feasible therapeutic approach for PCa or urothelial cancer harboring 
FGFR3 fusion or FGFR3 point mutation. 
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Chapter I: In vitro and in vivo characterisation of ASP9521: 
a novel, selective, orally bioavailable inhibitor of 17β-
hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3) 
 
1. Introduction 
Ever since the pioneer work by Huggins and Hodges more than 70 years ago [44, 45], 
androgens are known to play a pivotal role in the growth and perpetuation of prostate 
cancer (PCa) cells [46]. Consequently, androgen deprivation therapy (ADT) has become 
a standard component of therapy for patients with advanced PCa [47]. It often consists of 
medical castration using LH-RH agonists or antagonists, which target testosterone (T) 
production by the testes. Although most prostate tumors initially respond well to 
castration, the majority eventually (i.e. after a median time of 2–3 years) progress despite 
castrate serum T levels. This is defined as castration-resistant PCa (CRPC) [47-49]. 
Several mechanisms have been implicated in the development of CRPC, few of which 
may act independently of androgen receptor (AR) signaling, e.g. through upregulation of 
anti-apoptotic molecules, activation of c-myc, alterations in the PI3K/Akt/mTOR 
pathway or aberrant activation of other growth and survival pathways [47-49]. However, 
the major mechanisms involved in CRPC development rely on either ligand-dependent 
or ligand-independent continuous activation of the AR [47-49]. Ligand-independent 
activation may arise from adaptive changes in the AR –including amplifications, 
mutations, splice variants and/or post-translational modifications, allowing AR activation 
by alternate ligands or cross-talk with other signalling pathways. However, most 
abundantly, the AR is activated by its proper ligands, i.e. by androgens. Although surgical 
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or medical castration with LH-RH agonists or antagonists reduce serum T levels by 90–
97%, the total androgen pool in the circulation and intraprostatic levels of 
dihydrotestosterone (DHT) are only reduced by approximately 60% [49, 51]. These 
‘androgens that are untouched by castrative efforts’ are formulated either via conversion 
of so-called ‘weak’ androgens, previously synthesized by the adrenal glands, into DHT in 
peripheral tissues, or via increased intratumoral (intracrine) de novo synthesis of 
androgens, often due to upregulation of enzymes involved in steroidal biosynthesis [47-
49]. 
One of the key enzymes involved in adrenal and de novo intratumoural steroidal 
biosynthesis is aldo-keto reductase 1C3 (AKR1C3), also called 17β-hydroxysteroid 
dehydrogenase type 5 (17βHSD5). This enzyme plays a crucial role in the synthesis of 
DHT, by catalysing the conversion of the adrenal androgens dehydroepiandrosterone 
(DHEA), androstenedione (AD) and 5α-androstanedione into DHT (Fig. 1-1) [19]. 
AKR1C3 is highly expressed in PCa cells [20-23], and its expression increases with 
increasing tumor aggressiveness [24], as demonstrated by upregulated AKR1C3 levels in 
patients with CRPC compared with benign prostate and early stage PCa [25-31]. This is 
one of the reasons why AKR1C3 has been implicated in CRPC progression, and is the 
target for ASP9521, a novel AKR1C3 inhibitor. 
Based on the above-mentioned concepts, the overall objective of the current study was 
to ascertain if inhibition of AKR1C3 by ASP9521 would lead to reduced adrenal 
androgen biosynthesis and utilization in PCa tissue. Three fundamental questions were 
formulated: 1) Does AKR1C3 mediate conversion of adrenal androgens into T in 
preclinical models of CRPC?; 2) Does ASP9521 selectively inhibit AKR1C3?; 3) Where 
does ASP9521 accumulate, in PCa tissue or in plasma? The results of the study described 
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in this manuscript indicate that ASP9521 selectively inhibits AKR1C3, thereby reduces 
prostatic intratumoral androgens and PSA production. These observations led to a phase 
I/II study to investigate the safety, tolerability and anti-tumor activity of ASP9521 in 
patients with metastatic CRPC [52]. 
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2. Materials and Methods 
2.1. Synthesis of ASP9521 and crystal structure 
ASP9521 is a 1-{1-[(5-methoxy-1H-indol-2-yl)carbonyl] piperidin-4-yl}-2-
methylpropan-2-ol synthesized at Astellas Pharmaceutical Co. Ltd. (Tsukuba, Japan). It 
was discovered through a high-throughput screening approach to identify compounds 
inhibiting AKR1C3-mediated conversion of AD into T and subsequent in vitro and in 
vivo optimization of a lead compound with a non-steroidal scaffold. The synthesis of 
ASP9521 and the crystal structure of AKR1C3 in complex with ASP9521 have been 
reported elsewhere [53]. 
 
2.2. Cell lines and stable transfection 
HEK293 cells, a cell line derived from human embryonic kidney cells, and LNCaP 
cells (American Type Culture Collection, Manassas, VA, USA), a cell line commonly 
used as a model for castration-sensitive human PCa, were cultured in DMEM (Sigma-
Aldrich, St. Louis, MO, USA) and RPMI-1640 (Sigma-Aldrich) with 10% heat-
inactivated fetal bovine serum (FBS; Sigma-Aldrich), respectively. As endogenous 
expression levels of AKR1C3 are very low in both cell lines [20, 54], I established 
HEK293 and LNCaP cells stably expressing AKR1C3, i.e. HEK293-AKR1C3 and 
LNCaP AKR1C3. The cDNAs encoding human or cynomolgus monkey AKR1C3 with a 
FLAG-tag in the N-terminus were cloned into a pcDNA3.1 vector (Life Technologies, 
Carlsbad, CA, USA). Cells were transfected with pcDNA3.1-AKR1C3 (human or 
monkey; 10 μg DNA) using FuGENE® 6 Transfection Reagent (30 μL) (Promega, 
Fitchburg, WI, USA), according to the manufacturer’s instructions. Stable transfectants 
were selected in media containing 0.5–1.0 mg/mL geneticin (Invitrogen, Minato-ward, 
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Tokyo, Japan). AKR1C3 protein expression levels in parental cells and stable 
transfectants were examined by Western blot analysis. 10 μg protein from cell lysates was 
loaded and separated using SDS-PAGE, transferred to a PVDF membrane and probed 
with 3 μg/mL mouse monoclonal anti-AKR1C3 antibody (Sigma-Aldrich; clone NP6. G6. 
A6). CWR22R cells, a cell line derived from a human PCa xenograft, which 
endogenously expresses human AKR1C3, were kindly provided by Dr. Gregory CW 
(University of North Carolina, Raleigh, NC, USA) and maintained by in vivo passage in 
male Balb/c athymic nude mice (Charles River Japan Inc., Atsugi-City, Kanagawa-Pref, 
Japan). 
 
2.3. In vitro enzyme assay 
ASP9521 and AD (Sigma-Aldrich) were dissolved separately in dimethyl sulfoxide 
(DMSO), and then diluted with 100 mmol/L potassium phosphate buffer (pH 6) to final 
concentration of 30–10,000 nmol/L and 10 μmol/L, respectively. To obtain human 
AKR1C3 enzyme or AKR1C3 homologues from other species, E. coli BL21 strain (GE 
Healthcare Life Sciences, Hino-City, Tokyo, Japan) were transformed with pGEX-2T 
vector (GE Healthcare Life Sciences) containing human AKR1C3 (NM_003739), 
cynomolgus monkey AKR1C3 (17βHSD5; DQ266251) , rat AKR1C1 (NM_001033697) 
or mouse AKR1C6 (NM_030611) (see also: 
http://www.ncbi.nlm.nih.gov/gene/?term=hsd17b5) [55], followed by purification of 
the respective enzymes from these strains. Each purified enzyme was diluted with 
20 mmol/L NADPH, 2% CHAPS buffer and 100 mmol/L potassium phosphate buffer 
(pH 6). About 5 μg/mL enzyme was added to the reaction mixture containing ASP9521 
and AD. Reaction mixtures containing human or cynomolgus monkey AKR1C3 were 
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incubated at room temperature (RT; 20°C) for 1.5 h, while mixtures containing rat or 
mouse homologues were incubated at RT for 0.5 h. T levels in the reaction mixture were 
determined using Wallac DELFIA Testosterone reagents® (PerkinElmer Life Sciences 
Inc., MA, USA), based on the time-resolved fluorescence assay methods (i.e. competition 
between fluorescently labeled T and sample T for binding sites on polyclonal T 
antibodies). Fluorescence intensity was measured using a multi-well plate reader ARVO 
(PerkinElmer Life Sciences Inc.). 
 
2.4. AKR1C enzyme assay by monitoring NADPH oxidation 
Recombinant human enzymes AKR1C3 and AKR1C2 were purified from E. coli BL21 
strain (GE Healthcare Life Sciences). All assays were performed on SAFIRE 
spectrophotometer (Tecan Group Ltd., Männedorf, Switzerland). The potency of 
ASP9521 was determined by measuring its ability to inhibit NADPH-dependent 
reduction of 9,10-phenanthrenequinone (9,10-PQ) catalysed by human AKR1C as 
previously described [56]. Purified AKR1C3 or AKR1C2 (10 μg/mL), 9,10-PQ (4 
μmol/L) (Wako chemicals, Tokyo, Japan), NADPH (200 μmol/L) and ASP9521 were 
mixed in 100 mM potassium phosphate buffer (pH 6.0) to give a total volume of 80 μL, 
and incubated at RT for 20 min. The change in absorbance of NADPH at 340 nm at RT 
was measured. The amount of oxidation of NADPH in the presence of the compound was 
obtained as a relative value, with the amount of NADPH in the absence of the enzyme set 
at 0%, and the amount of NADPH in the absence of ASP9521 set at 100%. The IC50 
values were calculated using Sigmoid-Emax model non-linear regression. 
 
2.5. Cell-based AKR1C3 enzyme assay 
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HEK293-AKR1C3 cells or CWR22R cells, obtained by excising xenografted PCa 
tumors from mice and digesting them with 0.1% protease from Streptomyces griseus 
(Sigma-Aldrich), were seeded in 96-well plates at 2 × 104 cells/100 μL/well in medium 
(DMEM for HEK293-AKR1C3 cells; RPMI-1640 for CWR22R cells) supplemented 
with 10% heat-inactivated charcoal-dextran-stripped FBS (Gemini Bio-Products, CA, 
USA). After overnight incubation at 37 °C in 5% CO2, AD (final concentration 
300 nmol/L) was added to each well, with or without ASP9521. Four hours after 
incubation, the cell supernatants were collected to measure T concentration using Wallac 
DELFIA Testosterone reagents® according to the manufacturer’s instructions. IC50 values, 
defined as 50% inhibition of the conversion from AD into T, were calculated using 
Sigmoid-Emax model nonlinear regression. 
 
2.6. In vitro cell proliferation/PSA expression assay 
LNCaP-AKR1C3 cells stably expressing human AKR1C3 were seeded in 96-well 
plates at 1 × 104 cells/100 μL/well in RPMI-1640 medium supplemented with heat-
inactivated charcoal-dextran-stripped FBS (1% for the PSA expression assay and T 
measurement and 5% for the cell proliferation assay). After 24 h incubation, AD was 
added to each well with or without ASP9521 (0.3-100 nmol/L). The cell culture media 
were collected 24 h after administration of AD to measure T concentration and 6 days 
after administration of AD to measure either PSA levels using Human Kallikrein 3/PSA 
Quantikine® ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA) or cell 
proliferation using Cell-Titer Glo (Promega). For comparison of cell morphology 
between LNCaP cells and LNCaP-AKR1C3 cells, cells were supplemented with T, AD 
or DHEA (all reagents purchased from Sigma-Aldrich) (final concentration for each 
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reagent: 10 nmol/L in RPMI-1640 medium supplemented with 10% heat-inactivated 
charcoal-dextran-stripped FBS) for 7 days and morphology was assessed using a Nikon 
ECLIPSE Ti microscope (magnification 100×). 
 
2.7. In vivo model for intracrine T synthesis in CWR22R xenografts 
All experiments were performed in accordance with the regulation of the Animal Ethics 
Committee of Astellas Pharma Inc. Male Balb/c athymic nude mice (Charles River Japan 
Inc.) (4–6 weeks old) were used for the CWR22R xenograft model and were castrated 
before tumor implantation. Mice were maintained on a standard diet throughout the 
experiments under specific-pathogen-free conditions. Established CWR22R tumors from 
3 host mice were minced into small fragments and digested with protease (0.1%) from 
Streptomyces griseus (Sigma-Aldrich). The digested cells were suspended in RPMI-1640 
medium with 20% FBS and then mixed with Matrigel® (Becton Dickinson Co., NJ, USA) 
(1:1 v/v) solution to a concentration of 1 × 107 cells/mL. Approximately 100 μL of the 
cell suspension was subcutaneously injected into the flank of each castrated mouse. 
Approximately 3 weeks after implantation, mice carrying CWR22R tumors with similar 
sizes were divided into different groups (n=6 for each group). A control group for 
background (BG) intratumoral T concentration (no AD, no ASP9521) and a placebo 
group (AD, no ASP9521) were treated with vehicle (0.5% methyl cellulose), while the 
other groups were treated with ASP9521 (single oral administration directly into the 
mouth of the mice; 1, 3 or 10 mg/kg). AD (1 ng/100 mm3) was injected directly into the 
xenografted tumors 1 h before mice were sacrificed. This lag time of 1 h was chosen 
based on pilot experiments in the absence of ASP9521, showing that intratumoral T 
production reached a maximum 1 h after AD administration. 
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Blood samples were obtained from the central vein just before the sacrifice. Tumor 
tissues were removed, weighed and homogenated with 200 mmol/L phosphate buffer 
(pH 7.4). T was extracted by tert-butyl methyl ether and T concentrations of the 
reconstituted extracts were determined using Wallac DELFIA Testosterone reagents®. 
ASP9521 concentrations in tumor tissue or plasma were determined using the high-
performance liquid chromatography (Waters Alliance 2690 HPLC separation module, 
Waters Corporation, Milford, MA, USA)-mass spectrometry/mass spectrometry 
(API4000, AB SCIEX, Framingham, MA, USA) (HPLC-MS/MS) method. 
 
2.8. Accumulation of ASP9521 in HEK293 xenografts 
To investigate the role of AKR1C3 in the accumulation of ASP9521 in tumor tissue, 
HEK293 cells with or without AKR1C3 expression were xenografted into male Balb/c 
athymic nude mice (Charles River Japan Inc.) (5–6 weeks old). HEK293(−AKR1C3) 
cells were cultured in vitro in DMEM supplemented with 10% FBS and were dispersed 
in PBS (Sigma-Aldrich). The dispersed cells were mixed with Matrigel® (1:1 v/v; final 
concentration 3 × 107 cells/mL), and about 100 μL of the mixture was subcutaneously 
injected into the flank of each mice. Approximately 2–3 weeks after implantation, mice 
carrying HEK293 or HEK293-AKR1C3 tumors with similar sizes were selected and 
randomly divided into 5 groups (n=3 for each group). All groups were treated with 
ASP9521 (single oral administration; 3 mg/kg). Plasma (from the central vein) and tumor 
tissues were collected at 0.25, 0.5, 1, 2 and 4 h after administration of ASP9521, and 
ASP9521 concentrations were determined using the HPLC-MS/MS method. 
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3. Results 
3.1. AKR1C3 is required for adrenal hormone conversion to T and PSA 
production  
LNCaP cells and LNCaP cells stably expressing AKR1C3 (LNCaP-AKR1C3) (Fig. 1-
2) were supplemented with T, AD or DHEA. After supplementation with T, cell 
morphology was similar between both cell lines. However, supplementation with the 
adrenal androgens AD or DHEA induced a neuroendocrine-like phenotype in LNCaP 
cells, but not in LNCaP-AKR1C3 cells (Fig. 1-3). Similarly, LNCaP cells secreted lower 
levels of T and PSA in the culture medium than LNCaP-AKR1C3 cells (Fig. 1-4). 
Moreover, in LNCaP-AKR1C3 cells, ASP9521 inhibited both AD (10 nmol/L)-induced 
PSA production and cell proliferation in a concentration-dependent manner, with IC50 
values of 11 nmol/L and 6.6 nmol/L, respectively (Fig. 1-5). 
 
3.2. ASP9521 selectively inhibits AKR1C3 activity in CRPC 
In vitro, ASP9521 inhibited the conversion of AD into T by recombinant human and 
cynomolgus monkey AKR1C3 in a concentration-dependent manner, with IC50 values of 
11 and 49 nmol/L, respectively. In contrast, ASP9521 did not inhibit the conversion by 
rat and mouse homologues (AKR1C1 and AKR1C6, respectively) up to a concentration 
of 10 μmol/L. In an in vitro assay to evaluate the potency of ASP9521, inhibition of 
AKR1C-dependent oxidation of NADPH was monitored. ASP9521 showed moderately 
high selectivity (>100-fold) for human AKR1C3 (IC50: 120 nmol/L) over the human 
isoform AKR1C2 (IC50: >20,000 nmol/L). 
In HEK293 cells stably expressing human or cynomolgus monkey AKR1C3 (HEK293-
AKR1C3), ASP9521 inhibited conversion from AD into T in a concentration-dependent 
manner, with IC50 values of 1.9 and 6.2 nmol/L, respectively. Similarly, in CWR22R cells, 
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ASP9521 inhibited AD-induced T production in a concentration-dependent manner, with 
an IC50 of 0.88 nmol/L. Consistent with that, in murine models harboring CWR22R 
xenograft tumors, single oral administration of ASP9521 suppressed AD-induced 
intratumoral T production in a dose-dependent manner (2 h after administration of 
ASP9521: 52% inhibition for 3 mg/kg dose and 103% inhibition for 10 mg/kg dose) (Fig. 
1-6). Moreover, this inhibitory effect was maintained for 24 h after single oral 
administration of ASP9521 (Fig. 1-7). 
 
3.3. AKR1C3-dependent accumulation of ASP9521 in prostate tumors 
To investigate ASP9521 accumulation, the concentration of ASP9521 in plasma and 
tumor tissue was measured over time in nude mice bearing HEK293 tumors with or 
without AKR1C3 expression. After single oral administration of ASP9521, plasma 
concentrations of ASP9521 reached maximum values within 0.25 h (mean: 767.3 ng/mL 
and 648.2 ng/mL for HEK293 and HEK293-AKR1C3 cells, respectively), but decreased 
rapidly thereafter (Fig. 1-8). Similarly, the intratumoral concentration of ASP9521 in 
HEK293 tumors lacking AKR1C3 expression rapidly decreased from 845.8 ng/g after 
0.25 h to undetectable levels after 4 h. In contrast, in HEK293 tumors expressing 
AKR1C3, the maximum intratumoral ASP9521 concentration was considerably higher 
(mean: 1,905.0 ng/g after 0.25 h), and elevated ASP9521 levels were maintained for at 
least 4 h. These results suggest that accumulation of ASP9521 in tumor tissue depends on 
AKR1C3 expression. 
 
21 
 
4. Discussion 
The principle findings of this study relate to the inhibitory activity of ASP9521. The 
observations suggest that inhibition of AKR1C3 by ASP9521 in preclinical models of 
CRPC: 1) reduces androgen biosynthesis and PSA production, 2) is selective and 3) is 
maintained in the prostatic cancer tissue and not in plasma. In light of these data, 
ASP9521 was tested in a pilot phase I/II study in men with metastatic CRPC progressing 
after chemotherapy [52]. I hypothesized that administration of ASP9521 to patients with 
castrate levels of T would lead to complete suppression of androgen biosynthesis, by 
targeting mechanisms of hormonal drug resistance in CRPC [48-50], i.e. de novo 
intratumoral steroidogenesis through upregulation of AKR1C3 [57, 58] and ligand 
independent activation of AR signaling [59]. However, the planned phase I/II study was 
terminated prematurely due to lack of observed change to pharmacodynamic markers of 
activity [52]. 
Selectivity of ASP9521 for AKR1C3 was investigated using various AKR1C 
homologues and isoforms. ASP9521 was shown to selectively inhibit conversion of AD 
into T by human and cynomolgus monkey AKR1C3, but not by rat (AKR1C1) and mouse 
(AKR1C6) homologues [60]. Furthermore, ASP9521 showed high selectivity for 
AKR1C3 over its closely related isoform AKR1C2. Selectivity for AKR1C3 in PCa tissue 
is an absolute requirement for AKR1C inhibitors, as the isoforms AKR1C1 and AKR1C2 
are both involved in catabolism and deactivation of DHT within the prostate at steady 
state (Fig. 1-1) [61, 62]. Thus, inhibition of these isoforms would potentially lead to 
increased DHT tissue levels, increased AR signaling and PCa progression.  
The selectivity of ASP9521 spans more than inhibition of the AKR1C3 enzyme, but 
also relates to its lack of interference of precursor biosynthesis pathway components, 
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unlike that of other novel androgen biosynthesis inhibitors, such as abiraterone acetate 
(AA) (Fig. 1-1). AA targets CYP17A1 hydroxylase/lyase, an enzyme that converts 
pregnenolone and progesterone into DHEA and androstenedione via 2 subsequent 
reactions, catalyzed by CYP17α-hydroxylase and CYP17,20-lyase. However, inhibition 
of CYP17α-hydroxylase also decreases serum cortisol levels, leading to a subsequent rise 
in adrenocorticotropic hormone and mineralocortoids upstream of CYP17α-hydroxylase 
[63]. To suppress potential side effects related to this mineralocorticoid excess, AA 
requires coadministration with steroids such as prednisone. In contrast, ASP9521 acts 
further downstream in the steroid biosynthesis pathway and does not interfere with 
glucocorticoid metabolism (Fig. 1-1). So, ASP9521 may not require coadministration 
with prednisone [19]. In addition, ASP9521 was shown not to have any appreciable 
affinity for testosterone, oestrogen, glucocorticoid, mineralocorticoid or progesterone 
receptors (ASP9521 (10 μmol/L) had no appreciable affinity.). As such, ASP9521 itself 
is thought to be devoid of androgenic activity. 
AKR1C3 catalyzes both the conversion of DHEA and AD into androstenediol and T 
via the ‘classical’ pathway, and the conversion of 5α-androstanedione into DHT via the 
‘alternative’ pathway (Fig. 1-1) [19], thereby increasing intratumoral steroidogenesis. 
Upregulation of AKR1C3 has been suggested to be an adaptive response to androgen 
deprivation or to inhibition of AR activity [29, 31]. So, it is not surprising that prior 
treatment with AA was recently reported to be associated with increased levels of 
AKR1C3 expression [57, 58]. Taken together, administration of ASP9521 following 
progression on AA is a scientifically plausible path for further investigation. A limitation 
to the current study is the fact that we did not assess ASP9521 inhibitory activity in 
combination with AA or post AA treatment. 
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Although the current study appropriately demonstrates the inhibition of AKR1C3 by 
ASP9521, further limitations to the results were noted. The selectivity of ASP9521 for 
AKR1C3 over AKR1C1 was not specifically investigated. However, ASP9521 showed 
>100-fold selectivity for AKR1C3 over AKR1C2, and AKR1C1 shares 98% sequence 
identity to AKR1C2, with both isoforms differing only in 1 amino acid at respective active 
sites [19, 64, 65]. Therefore, it is very likely that ASP9521 is also highly selective for 
AKR1C3 over AKR1C1. I did not assess the inhibitory potential of ASP9521 on the 
‘backdoor’ pathway of androgen biosynthesis, but mainly on the ‘classical’ and 
‘alternative’ pathways. The ‘backdoor’ pathway requires 5α-reductase activity as a first 
step in the conversion of pregnenolone and progesterone into androstanediol (3α-diol), 
which is then back-converted to DHT (Fig. 1-1) [58, 66, 67]. This pathway has been 
implicated in CRPC as contributing to hormonal drug resistance. I also did not evaluate 
the effect of ASP9521 on the levels of DHT and/or precursor steroidal hormones in the 
biosynthesis pathway. Knowledge of the impact of ASP9521 on these endocrine levels 
would allow for a more well-rounded understanding of the activity and full mechanistic 
profile of ASP9521. 
In summary, the current study, even with its limitations, demonstrated that ASP9521 is 
a potent, selective, orally bioavailable inhibitor of AKR1C3-mediated conversion of AD 
into T, both in vitro and in vivo in CWR22R xenografted castrate mice. Furthermore, 
expression of AKR1C3 in tumor tissue was found to be a prerequisite for intratumoral 
accumulation of ASP9521. These results provided the rationale for testing ASP9521 in 
patients with mCRPC. In patients with mCRPC, ASP9521 demonstrated dose-
proportional increase in exposure over the doses evaluated, with an acceptable safety and 
tolerability profile. However, the novel androgen biosynthesis inhibitor showed no 
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relevant evidence of clinical activity [52]. The discrepancy between the preclinical and 
clinical results illustrates the complexity of T synthesis pathway in CRPC. Further 
research is needed to find out why the promising preclinical results could not be 
reproduced in the clinical setting. 
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5. Figures 
 
Figure 1-1. Androgen biosynthesis pathways.   
The ‘classical’, ‘alternative’ and ‘backdoor’ pathways of androgen biosynthesis are 
indicated in green, purple and orange, respectively. The target enzymes of 
abiraterone/orteronel and ASP9521 are indicated in red. AKR1C1: aldo-keto reductase 
family 1, member C1; AKR1C2: aldo-keto reductase family 1, member C2 (3α-
hydroxysteroid dehydrogenase type III); AKR1C3: aldo-keto reductase family 1, member 
C3 (17β-hydroxysteroid dehydrogenase V); CYP11A1: cytochrome P450, family 11, 
subfamily A, polypeptide 1; CYP17A1: cytochrome P450, family 17, subfamily A, 
polypeptide 1; DHEA: dihydroepiandrosterone; DHT: dihydrotestosterone; HSD17B10: 
17β-hydroxysteroid dehydrogenase X; HSD17B2: 17β-hydroxysteroid dehydrogenase II; 
HSD17B3: 17β-hydroxysteroid dehydrogenase III; HSD17B6: 17β-hydroxysteroid 
dehydrogenase VI; HSD3B1,2: 3β-hydroxysteroid dehydrogenase 1,2; RDH5: retinol 
dehydrogenase 5; RODH4: 17β-hydroxysteroid dehydrogenase VI; SRD5A1,2: steroid 
5α-reductase 1,2 
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Figure 1-2. Comparison of AKR1C3 expression levels in CWR22R, HEK293, 
LNCaP-AKR1C3 and LNCaP cell lines by Western blot analysis, using mouse 
monoclonal anti-AKR1C3 antibody.  
10 μg protein was loaded per lane and α-tubulin was used as a loading control.   
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Figure 1-3. Comparison of cell morphology between LNCaP cells and LNCaP-
AKR1C3.  
Cells were supplemented with T, AD or DHEA for 7 days and morphology was assessed. 
Final concentration for each reagent: 10 nmol/L in RPMI-1640 medium supplemented 
with 10 % heat-inactivated charcoal-dextran-stripped FBS  
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Fig. 1-4. Comparison of (A) testosterone and (B) PSA formation between LNCaP 
cells and LNCaP cells stably expressing AKR1C3 (LNCaP-AKR1C3).  
Cells were treated with AD at various concentrations (range: 10–300 nmol/L). 
Testosterone and PSA concentration in the medium were measured 24 h and 6 days after 
administration of AD, respectively.   
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Fig. 1-5. Inhibitory effect of ASP9521 on AD-dependent (A) PSA production and (B) 
cell proliferation in LNCaP prostate cancer cells stably transfected with AKR1C3. 
PSA production and cell proliferation were measured 6 days after administration of AD 
(final concentration 10 nmol/L) and various concentrations of ASP9521. Results are 
expressed as percentage inhibition compared with PSA production/cell proliferation in 
the absence of ASP9521  
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Fig. 1-6. Dose dependency of inhibitory effect of ASP9521 on AD-induced 
intratumoral T production in mice bearing CWR22R xenograft.  
Mice were sacrificed 2 h after administration of a single oral dose of ASP9521. For each 
group, mean ± standard error is depicted (n=6 per group). Percentage inhibition of 
intratumoral T was calculated taking the mean value for the placebo group (AD only, no 
ASP9521) as 0% inhibition and that for the BG group (no AD, no ASP9521) as 100% 
inhibition. #P<0.05 vs BG group (Student’s t-test); *P<0.05 vs placebo group (Dunnett’s 
test)  
 
  
31 
 
 
 
Fig. 1-7. Duration of inhibitory effect of ASP9521 on AD-induced intratumoral T 
production in mice bearing CWR22R xenograft. 
Mice were treated with ASP9521 (3 mg/kg, po) or placebo and sacrificed 0.25, 0.5, 1, 2, 
4, 8 and 24 h afterwards (n=6 per group). AD was injected into the xenografts 1 h before 
the sacrifice. For each group, mean ± standard error is depicted. The dashed line indicates 
the background level of intratumoral T production (no AD, no ASP9521) 
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Fig. 1-8. Concentration of ASP9521 over time in plasma (ng/mL) and tumor tissue 
(ng/g) of mice bearing HEK293 xenograft with or without AKR1C3 expression.  
Mice were treated with ASP9521 (3 mg/kg, po) and sacrificed 0.25, 0.5, 1, 2 and 4 h 
afterwards (n=3 per group). For each group, mean ± standard deviation is depicted 
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Chapter II: ASP5878, a selective FGFR inhibitor, to treat 
FGFR3-dependent urothelial cancer with or without 
chemoresistance 
 
1. Introduction 
Urothelial cancer can arise anywhere along the epithelial lining of urinary tract, 
including the bladder, renal pelvis and ureter. Although urothelial cancers arising in these 
various locations have similar morphology and gene expression profile [32], urothelial 
cancer occurs most frequently in the bladder. Bladder cancer is the most common 
malignancy involving the urinary system. Bladder cancer is mainly divided into two 
groups by stage. The stage classification differentiates between non-muscle invasive (Tis, 
Ta and T1) and muscle-invasive tumors (T2, T3 and T4) according to the depth of 
invasion. The standard therapy of muscle-invasive bladder cancer is the combination of 
chemotherapeutic agents (GC and MVAC). However, despite reasonable response rates 
to chemotherapy in patients with locally advanced or metastatic bladder cancer, long-term 
progression-free survival rates remain insufficient [34], which is thought to be caused by 
the induction of MDR1 overexpression or the alterations in the apoptotic machinery 
including overexpression of c-MYC, an oncoprotein [35, 36]. Therefore, effective drugs 
against chemotherapy-resistant bladder cancer are eagerly needed. 
The mammalian FGF/FGFR family comprises 18 ligands and 4 main receptors 
(FGFR1–4). FGFs induce FGFR dimerization, followed by FGFR autophosphorylation 
and activation of downstream signaling pathways. In a variety of human cancers, aberrant 
activation of FGF/FGFR signaling promotes cellular proliferation, migration/invasion 
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and angiogenesis [37]. Five different FGFR3 point mutations such as R248C, S249C, 
G372C, Y375C, and K652E account for more than 90% of the point mutations of FGFR3, 
and S249C is the most common (48%) in bladder cancer [39]. The frequency of FGFR3 
point mutation in muscle-invasive bladder cancer is lower than that in non-muscle 
invasive bladder cancer [15% (7/47): invasive, 58% (58/100): non-invasive] [39]. 
Another report shows that the frequencies of FGFR3 point mutations in primary muscle 
invasive urothelial tumors and metastases are 2% (2/161) and 9% (3/33), respectively 
[68]. Recently, it has been also reported that FGFR3-TACC3 and FGFR3-BAIAP2L1, 
fusion genes were identified in some urothelial cancer cell lines and cancer tissue samples 
[40, 41]. FGFR3 fusion genes are observed in 3% (3/114) of muscle-invasive urothelial 
cancer [69]. Therefore, clinical trials of FGFR inhibitors in urothelial cancer harboring 
FGFR3 fusion genes or point mutations are ongoing [70]. The clinical relevance of 
FGFR3-TACC3 has been suggested by the clinical report of JNJ-42756493, a pan-FGFR 
inhibitor, which exerts 3 out of 4 partial responses among patients with tumors harboring 
FGFR3-TACC3 fusion genes [71]. In a subset of urothelial cancer patients harboring 
FGFR3 gene alternation (FGFR3 fusion gene and point mutation) treated with BGJ398, 
the overall response rate in 25 evaluable patients was 36% and included 1 unconfirmed 
complete response and 8 partial responses [72]. In light of these reports, FGFR3 has been 
considered as an attractive target for novel therapy in urothelial bladder cancer. 
In this thesis, I describe the preclinical profile of ASP5878, which is a selective FGFR 
inhibitor under clinical investigation (NCT 02038673), targeting FGFR3-fusion or -
mutation positive urothelial bladder cancer. Interestingly, ASP5878 suppressed the 
growth of FGFR3-fusion or -mutation positive urothelial cancer cell lines even after the 
acquisition of chemoresistance. My data indicate that ASP5878 is a potentially effective 
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therapeutic agent for urothelial cancer patients whose tumors express FGFR3 mutation 
or -fusion after the acquisition of gemcitabine- or adriamycin- resistance. 
36 
 
2. Materials and Methods 
2.1. Reagents 
2-[4-({5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl}amino)-1H-
pyrazol-1-yl]ethan-1-ol [ASP5878 [73]] was synthesized at Astellas Pharma Inc. (Tokyo, 
Japan). ASP5878 was dissolved in DMSO or suspended in 0.5% methyl cellulose for in 
vitro and in vivo experiments, respectively. Gemcitabine was purchased from Eli Lilly 
Inc. (Indianapolis, IN, USA), and was dissolved in water or saline for in vitro and in vivo 
experiments, respectively. Adriamycin was purchased from Wako Pure Chemical 
Industries Ltd. (Osaka, Japan), and was dissolved in water. 
 
2.2. Cell lines 
HT-1197, HT-1376, J82, RT4, SW 780, TCCSUP, UM-UC-3, NCI-H1581 and 
Hep3B2.1-7 were purchased from ATCC (Manassas, VA, USA). 647-V, BC-3C, BFTC-
905, CAL-29, KU-19-19, RT-112, SW-1710 and VM-CUB1 were purchased from DSMZ 
(Braunschweig, Germany). EJ138, U-BLC1, UM-UC-9 and UM-UC-14 were purchased 
from ECACC (Salisbury, UK). KMBC-2 and T24 were purchased from JCRB Cell Bank 
(Osaka, Japan). BOY-12E, and JMSU-1 were provided by the RIKEN BRC (Tsukuba, 
Japan). HSC-39 was purchased from IBL (Takasaki, Japan). These cell lines were 
cultured according to the guidelines from the suppliers. 
To generate chemotherapy-resistant cell lines, UM-UC-14 and RT-112 cell lines were 
exposed to adriamycin and gemcitabine, respectively, whose concentrations were 
gradually increased up to 100 and 1000 ng/mL, respectively. Adriamycin-resistant UM-
UC-14 and gemcitabine-resistant RT-112 cell lines were maintained in the culture 
medium containing 50 ng/mL adriamycin and 1000 ng/mL gemcitabine, respectively. 
37 
 
 
2.3. In vitro cell growth assay 
HSC-39 was seeded into 96-well clear flat plates at 500 cells/well, Hep3B2.1-7 was at 
1000 cells/well, and other cells were at 2000 cells per well and incubated overnight. On 
the following day, the cells were exposed to ASP5878 for 4 days (JMSU-1) or 5 days 
(other cell lines). The cell viability was measured with CellTiter-GloTM (Promega, 
Madison, WI, USA). Data are presented as means from a single experiment performed in 
duplicate. 
 
2.4. MDR1 expression 
Immunoblotting was performed using mouse anti-MDR1 (D-11) monoclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-β-actin (13E5) 
monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA). 
MDR1 mRNA expression in adriamycin-resistant UM-UC-14 cell line was quantified 
by qPCR method using the following MDR1 and GAPDH primer sets; forward and 
reverse primer sequences for MDR1 were 5’-CCCATCATTGCAATAGCAGG-3’ and 
5’-GTTCAAACTTCTGCTCCTGA-3’, and forward and reverse primer sequences for 
GAPDH were 5’-CCTGACCTGCCGTCTAGAAAA-3’ and 5’-
CGCCTGCTTCACCACCTT-3, respectively. 
 
2.5. Inhibition of in vitro FGFR3 phosphorylation 
Cells were seeded in 100 mm dishes at 2 × 106 cells/10 mL/dish and cultured overnight. 
Media were replaced with ASP5878 containing media at the final concentrations of 0, 1, 
10, 100 and 1000 nmol/L, respectively. The final concentration of DMSO in each dish 
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was 0.1%. Following 2-hour incubation with ASP5878, cells were rinsed with PBS and 
collected. Cell pellet was obtained and lysed with cell lysis buffer containing phosphatase 
inhibitor (Thermo Fisher Scientific, Rockford, IL, USA) and protease inhibitor (Roche, 
Basel, Switzerland). Cell lysate was centrifuged and then supernatant was obtained as the 
sample for ELISA assay. Phosphorylated and total FGFR3 were measured by sandwich 
ELISA assay (DYC2719 and DYC766, R&D systems, Minneapolis, MN, USA). The ratio 
of phosphorylated FGFR3 to total FGFR3 is calculated according to the formula: 
(phospho FGFR3 concentration [pg/mL]) / (total FGFR3 concentration [pg/mL]). FGFR3 
phosphorylation rate to the DMSO-treated sample was calculated according to the 
formula: (phosphorylation ratio of ASP5878-treated sample) / (phosphorylation ratio of 
DMSO-treated sample) × 100 (%). 
 
2.6. Immunoblotting for the downstream signaling of FGFR3 and c-MYC 
Cells were seeded in 100 mm dishes at 2 × 106 cells/10 mL/dish and cultured 
overnight. Media were replaced with ASP5878 containing media at the final 
concentrations of 0, 1, 10, 100 and 1000 nmol/L respectively. The final concentration of 
DMSO in each dish was 0.01%. Following 2-hour (for ERK and phospho-ERK) or 48-
hour (for c-MYC) incubation with ASP5878, cells were rinsed with PBS and collected. 
The cells were lysed with cell lysis buffer (Cell Signaling Technology) containing 
phosphatase inhibitor (Thermo Scientific) and protease inhibitor (Roche), and protein 
levels of ERK, c-MYC and actin, and phosphorylation levels of ERK were determined 
by immunoblotting. Antibodies were obtained from following sources: ERK (#9102; Cell 
Signaling Technology) and phospho-ERK (Thr202/Tyr204) (#9101; Cell Signaling 
Technology), actin (A5441; Sigma-Aldrich, St Louis, MO), c-MYC (#5605; Cell 
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Signaling Technology). 
 
2.7. In vivo tumor studies 
Five-week-old male nude mice (BALB/c nu/nu) were purchased from Charles River 
Japan, Inc (Kanagawa, Japan). All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee of Astellas Pharma Inc. Furthermore, 
Astellas Pharma Inc., Tsukuba Research Center was accredited by AAALAC 
International. UM-UC-14, RT-112 and gemcitabine-resistant RT-112 cell lines were 
subcutaneously inoculated into the flank of mice at 3 × 106, 1 × 106 and 1 × 106 
cells/0.1mL (Matrigel® : PBS=1:1)/mouse, respectively and allowed to grow. The mice 
with tumor were divided into 4 or 5 groups (n=5 or 10) so that the mean tumor volume of 
the groups were similar on day 0. ASP5878 (0.3-10 mg/kg) was administered orally once 
daily to these xenografted mice. Intravenous gemcitabine (100 mg/kg) was given to them 
twice a week. Tumor volume was determined by length × width2 × 0.5. Matrigel® were 
purchased from Corning Life Sciences (Tewksbury, MA, USA). 
 
2.8. In vivo FGFR3 phosphorylation 
Tumor samples were collected from UM-UC-14 tumor-bearing mice at 0.5, 1, 2, 4, 6, 
12, 18 and 24 hours after single dose of ASP5878 and vehicle. Frozen tumor samples 
were lysed with cell lysis buffer containing phosphatase inhibitor (Thermo Fisher 
Scientific) and protease inhibitor (Roche). Phosphorylated and total FGFR3 were 
measured by sandwich ELISA assay. 
 
2.9. Statistical Analysis 
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Values are expressed as the mean ± SE. Differences between groups were analyzed 
using Dunnett’s multiple comparison test. All data analysis was performed using the SAS 
statistical software (SAS Institute, Cary, NC), with P values less than 0.05 considered 
significant. 
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3. Results 
3.1. Kinase inhibition profile of ASP5878 
ASP5878 potently inhibited the tyrosine kinase activities of recombinant FGFR 1, 2, 3 
and 4 with IC50 values of, 0.47, 0.60 0.74 and 3.5 nmol/L, respectively. The selectivity of 
ASP5878 was profiled against a kinase panel of 128 human kinases. FGFRs, VEGFR2 
and FMS were inhibited by more than 50% by ASP5878 (200 nmol/L) [74]. 
 
3.2. Anti-proliferative profile of ASP5878 in urothelial cancer and other FGFR-
dependent cell lines 
ASP5878 inhibited cell growth of UM-UC-14 [FGFR3_S249C; [75]], RT-112 
[FGFR3-TACC3; [40]], RT4 [FGFR3-TACC3; [40]], SW 780 [FGFR3-BAIAP2L1; [41]] 
and JMSU-1 [FGFR1 overexpression; [76]] with IC50 values of less than 100 nmol/L (Fig. 
2-1). ASP5878, however, was inactive (IC50 values ≥300 nmol/L) against other urothelial 
cancer cell lines without FGFR genetic alterations (Fig. 2-1). Additionally, ASP5878 also 
inhibited cell proliferation of NCI-H1581 [FGFR1 amplification, lung; [77]], HSC-39 
[FGFR2 amplification, stomach; [78]], and Hep3B2.1-7 [FGF19 amplification, liver; 
[79]] which is known as a FGF19/FGFR4-dependent cell line (Table 2-1). Thus, ASP5878 
has potent anti-proliferative effects in human cancer cell lines harboring gene alterations 
in FGF or FGFR. 
 
3.3. Inhibitory effect of ASP5878 on FGFR3 and ERK phosphorylation in UM-
UC-14 and RT-112 cell lines 
ASP5878 (1, 10, 100 and 1000 nmol/L) decreased phosphorylated FGFR3 in UM-UC-
14 and RT-112 cell lines after 2 hours of treatment (Fig. 2-2a). ERK phosphorylation, a 
downstream signaling molecule in the cell lines, was inhibited by ASP5878 in a 
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concentration-dependent manner (Fig. 2-2b). Thus, ASP5878 inhibits FGFR3 
phosphorylation and ERK phosphorylation in urothelial cancer cell lines harboring 
FGFR3 gene alternations.  
 
3.4. Anti-proliferative effects of ASP5878 in urothelial cancer cell lines with 
acquired resistance to adriamycin or gemcitabine 
It has been reported that MDR1 mRNA levels in bladder cancer tissues are correlated 
with the resistance to adriamycin in bladder cancer patients [35]. I therefore established 
adriamycin-resistant UM-UC-14 cell line as described in Materials and Methods and 
compared MDR1 expression levels in the parental and the adriamycin-resistant UM-UC-
14 cell lines. The expression levels of MDR1 protein (Fig. 2-3a) and mRNA (Fig. 2-3b) 
in the adriamycin-resistant UM-UC-14 cell line were much higher than those in the 
parental cell line. Adriamycin exhibited 8.7-folds weaker anti-proliferative effect in the 
adriamycin-resistant UM-UC-14 cell line (IC50=58 ng/mL, 95% CI: 17-203, n=3) than 
that in the parental cell line (IC50=6.7 ng/mL, 95% CI: 2.3-20, n=3) (Fig. 2-3c). While, 
ASP5878 exerted anti-proliferative effects in both the parental and adriamycin-resistant 
UM-UC-14 cell lines with similar IC50 values of 8.7 (95% CI: 2.3-32, n=3) and 11 nmol/L 
(95% CI: 3.9-34, n=3), respectively (Fig. 2-3d).  
Gemcitabine is also one of the chemotherapeutic agents for invasive / metastatic 
bladder cancer. However, despite reasonable response rates to initial chemotherapy 
including gemcitabine in patients with locally advanced or metastatic bladder cancer, 
long-term progression-free survival rates remain insufficient [35]. Therefore, I 
established gemcitabine-resistant RT-112 cell line as described in Materials and Methods 
and examined effects of ASP5878 on the proliferation and downstream signaling of 
FGFR3 in the gemcitabine-resistant RT-112 cell line. Gemcitabine inhibited the 
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proliferation of the parental RT-112 cell line with IC50 value of 0.95 ng/mL (95%CI: 0.18-
5.0, n=3) but not inhibited that of the gemcitabine-resistant RT-112 cell lineup to 
1000ng/mL (Fig.2-4a). ASP5878 inhibited the proliferation of the parental and the 
gemcitabine-resistant RT-112cell lines with similar IC50 values of 8.7 (95% CI: 3.9-20, 
n=3) and 10nmol/L (95% CI: 3.7-27, n=3), respectively (Fig.2-4b) and decreased the level 
of ERK phosphorylation in the gemcitabine-resistant RT-112 cell line as with that in the 
parental cell line (Fig. 2-2b, 2-4c).It has been reported that gemcitabine-resistant cell 
growth in urothelial cancer cells is related to up-regulation of c-MYC expression which 
is involved in cell proliferation [36]. Up-regulation of c-MYC protein in the gemcitabine-
resistant RT-112 cell line was also observed (Fig. 2-4d). Interestingly, ASP5878 decreased 
the expression of c-MYC in both the gemcitabine-resistant RT-112 and the parental cell 
lines (Fig. 2-4d). From these findings, it is possible that ASP5878 can inhibit cell 
proliferation and c-MYC expression independent on gemcitabine-resistant status of 
urothelial cancer cell line harboring FGFR3 gene alternation. Thus, ASP5878 has growth 
inhibitory activities against urothelial cancer harboring FGFR3-TACC3 fusion or 
FGFR3_S249C even after the acquisition of adriamycin or gemcitabine resistance. 
 
3.5. Antitumor activities of ASP5878 in urothelial cancer xenograft models 
Once-daily oral administration of ASP5878 dose-dependently inhibited tumor growth 
and induced tumor regression at more than 1 mg/kg in UM-UC-14 subcutaneous 
xenograft mouse model (Fig. 2-5a). Single administration of ASP5878 (1, 3, and 10 
mg/kg) inhibited FGFR3 phosphorylation in UM-UC-14 subcutaneous tumor and the 
duration of inhibition was dose-dependent (Fig. 2-5b), which indicates a reasonable 
antitumor activity of ASP5878 in UM-UC-14 subcutaneous xenograft mouse model. 
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ASP5878 also dose-dependently inhibited tumor growth in RT-112 (Fig. 2-5c) and 
gemcitabine-resistant RT-112 (Fig. 2-5d) subcutaneous xenograft mouse models. Body 
weight was not affected at any dose of ASP5878 examined in these experiments (Fig. 2-
5e). Thus, ASP5878 has the antitumor activities in urothelial cancer models harboring 
FGFR3_S249C or FGFR3-TACC3 fusion after the acquisition of gemcitabine resistance. 
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4. Discussion 
FGFR tyrosine kinases are frequently activated by diverse genetic alterations in cancer, 
and therefore, FGFR inhibitors may be effective in patients with FGFR genetic alterations. 
In this study, I examined the therapeutic potential of ASP5878 in urothelial cancer cell 
lines and xenografts harboring FGFR3 gene alternations. ASP5878, an FGFR tyrosine 
kinase inhibitor with a high selectivity against a number of other kinases [74], has potent 
anti-proliferative effects on FGFR1, 2, 3 and 4-depencent cell lines (Table 2-1). In 23 
urothelial cancer cell lines, ASP5878 inhibited the proliferation of RT-112 and RT4 
harboring FGFR3-TACC3, SW 780 harboring FGFR3-BAIAP2L1, UM-UC-14 
harboring FGFR3_S249C and JMSU-1 harboring FGFR1 overexpression (Fig. 2-1). 
FGFR3-TACC3 displayed ligand-independent constitutive activation of FGFR3 kinase 
activity and dimerization through a coiled-coil domain in TACC3 [40, 73]. BAIAP2L1 
has Bin-Amphiphysin-Rvs (BAR) domain which contributes to dimerization and 
constitutive activity in FGFR3-BAIAP2L1 fusion protein [41]. FGFR3_S249C mutation 
induces disulfide bond formation by introducing an additional cysteine in the extracellular 
domain of FGFR3, thereby causing constitutive dimerization and activation of the 
receptor [80]. Aside from FGFR3 gene alternations, JMSU-1 cell line, an urothelial 
cancer cell line harboring FGFR1 overexpression, has been demonstrated to have FGFR1-
dependent cell growth activity by using FGFR1 siRNA [75]. These findings suggest that 
FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR3_S249C mutations and FGFR1 
overexpression may be predictors of the sensitivity to ASP5878 in urothelial cancer. 
Currently, combination chemotherapy such as MVAC and GC are the first-line therapy 
for metastatic bladder cancer patients. Unfortunately, the treatment success of bladder 
cancer is limited resulting in a median survival of 12 to 16 months [35]. Treatment failure 
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can be commonly caused by development of resistance to chemotherapy [34, 81]. 
MDR1 is a cell membrane efflux pump involved in drug resistance. Expression of 
MDR1 was detected in both pre- and post-chemotherapy tumor tissue samples from 
patients with bladder cancer and a higher expression in post-chemotherapy patients was 
reported [82, 83]. I also obtained adriamycin-resistant UM-UC-14 cell line harboring 
MDR1 overexpression by stepwise increasing concentrations of adriamycin (Fig. 2-3). In 
addition, some studies have highlighted the important role of c-MYC in the development 
of drug-resistant phenotypes in cancer [84, 85]. It has been reported that KU19-19/GEM, 
gemcitabine-resistant urothelial cancer cells, up-regulated c-MYC expression in the 
presence of gemcitabine and the growth of KU19-19/GEM cells was suppressed by KSI-
3716, a c-MYC inhibitor [36]. 
As is the case of KU19-19/GEM cells, I also successfully established gemcitabine-
resistant RT-112 cell line harboring c-MYC up-regulation by stepwise exposure to 
gemcitabine (Fig. 2-4). Furthermore, c-MYC overexpression has been observed in 
urothelial cancer tissues [86-88]. Thus, c-MYC is thought to be relevant to drug-
resistance in cancer. On the other hand, it has been reported that c-MYC expression was 
decreased by PD173074, an FGFR inhibitor, in lung cancer cell lines harboring FGFR1 
overexpression [89]. Activated ERK, a downstream molecule of FGFR, stabilizes c-MYC 
in melanoma cells [90]. In the present study, ASP5878 also inhibited ERK 
phosphorylation and induced c-MYC down-regulation in urothelial cancer cell line 
harboring FGFR3 gene alternation independent on gemcitabine resistant status (Fig. 2-
4d). These findings suggest that c-MYC expression may be regulated by the FGFR/ERK 
signaling pathway. 
Despite a lot of studies related to the mechanisms of chemoresistance, an effective 
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therapy for chemoresistant urothelial cancer is still unestablished. Recently, FGFR 
inhibitors such as BGJ398 and CH5183284/Debio1347 have been reported to have an 
antitumor effect in FGFR3-dependent urothelial cancer models [91, 92]. And also several 
FGFR inhibitors including BGJ398, CH5183284/Debio1347, JNJ-42756493 and 
AZD4547 are being developed for treatment of urothelial cancer. In a subset of urothelial 
cancer patients harboring FGFR3 gene alternation, JNJ-42756493 and BGJ398 exerted 
partial responses. However, these FGFR inhibitors haven’t been shown to have 
therapeutic potential against chemoresistant urothelial cancer in the preclinical models. 
Therefore, I evaluated ASP5878 for the treatment of chemoresistant urothelial cancer by 
using chemoresistant urothelial cancer cell lines. In adriamycin-resistant UM-UC-14 cell 
lines, MDR1 expression was increased (Fig. 2-3a) and ASP5878 inhibited the 
proliferation in common with the parent UM-UC-14 cell line (Fig. 2-3c). Furthermore, 
ASP5878 inhibited the cell growth in gemcitabine-resistant RT-112 cells in vitro and in 
vivo studies. (Fig. 2-4b, 2-5d). In addition to gemcitabine and adriamycin, cisplatin is also 
a key chemotherapeutic agent. However, I have not obtained the data that ASP5878 
inhibits cell proliferation in cisplatin-resistant cells, because we currently do not succeed 
in the establishment of cisplatin-resistant cells. In the present study, I demonstrated 
antitumor activities of ASP5878 using mouse models xenografted with urothelial cancer 
cell lines (Fig. 2-5). Patient-derived xenograft models are thought to be useful to make 
sure the efficacy of ASP5878 in urothelial cancer harboring FGFR3 gene alternation. 
These are future tasks to be confirmed. From these findings, ASP5878 may exert 
antitumor activity against adriamycin-resistant and gemcitabine-resistant urothelial 
cancer harboring FGFR3 gene alternations. 
Hyperphosphatemia has been commonly observed with other FGFR inhibitors (e.g. 
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JNJ-42756493 and BGJ398) [71, 72]. In line with the findings, ASP5878 also induced 
serum phosphate increase in rodents. The safety, pharmacokinetics, and 
pharmacodynamics of ASP5878 are currently evaluated in clinical phase I study. In 
addition to the safety information, it has been reported that T1/2 values of JNJ-42756493 
and BGJ398 are quite large according to clinical information of these compounds [71, 
93]. In the present study, I showed the duration of FGFR3 inhibitory activity after single 
administration of ASP5878 was relatively short in mice (Fig. 2-5b), which might be a 
benefit for the management of plasma phosphate levels. 
In conclusion, ASP5878, a selective FGFR inhibitor, showed potent anti-proliferative 
and antitumor activity in urothelial cancer cell line harboring FGFR3-TACC3, FGFR3-
BAIAP2L1 or FGFR3 point mutation and their tumor xenografted models. ASP5878 also 
inhibited the proliferation of adriamycin-resistant UM-UC-14 and gemcitabine-resistant 
RT-112 cell lines. These findings suggest that ASP5878, which is currently being 
evaluated in phase I clinical trials, has therapeutic potential against urothelial bladder 
cancers harboring FGFR3-TACC3, FGFR3-BAIAP2L1 or FGFR3 point mutation after 
the acquisition of gemcitabine- or adriamycin- resistance. 
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5. Table 
 
Table 2-1. Anti-proliferative effect of ASP5878 in FGFR-dependent cell lines. 
 
Data represent the mean of IC50 and 95% CI of 3 individual experiments. 
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6. Figures 
 
 
Fig. 2-1. Cell panel assay for the identification of ASP5878-sensitive bladder cancer 
cell lines. 
The 23 bladder cancer cell lines were treated with ASP5878 or 0.1% DMSO (control) for 
4 (JMSU-1) or 5 days (other cell lines). The cell viability on day 4 or day 5 was measured 
by quantitating the amount of ATP in cell lysate. The IC50 value of ASP5878 on the cell 
proliferation of each cell line was indicated with each bar graph. Data are presented as 
means from a single experiment performed in duplicate. 
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Fig. 2-2. Inhibitory effects of ASP5878 on FGFR3 and ERK phosphorylation in UM-
UC-14 and RT-112 cell lines. 
(upper) UM-UC-14 (a) and RT-112 (b) cell lines are incubated for 2 h with each 
concentration of ASP5878 or 0.1% DMSO. Cells are then lysed and assessed FGFR3 
phosphorylation rate by sandwich ELISA assay. (bottom) UM-UC-14 and RT-112 cell 
lines are incubated for 2 h with each concentration of ASP5878 or 0.01% DMSO. 
Phosphorylated ERK (p-ERK), ERK and actin were detected by immunoblotting.  
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Fig. 2-3. Anti-proliferative effect of ASP5878 in adriamycin-resistant UM-UC-14 cell 
line. 
(a) MDR1 protein expression in adriamycin-resistant UM-UC-14 (lane 2) and parental 
UM-UC-14 (lane 1) cell lines was detected by immunoblotting. (b) MDR1 mRNA 
expression in adriamycin-resistant UM-UC-14 cell line was detected by qPCR 
(normalized to parental UM-UC-14 cell line). (c, d) Anti-proliferative effect of 
adriamycin (c) and ASP5878 (d) in adriamycin-resistant UM-UC-14 (ADR-R) and 
parental UM-UC-14 cell lines. These cell lines were treated with ASP5878 or adriamycin 
for 5 days [control: 0.1% DMSO (ASP5878), water (adriamycin)]. Values are expressed 
as the mean ± SE from three separate experiments. 
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Fig. 2-4. Anti-proliferative effect of ASP5878 in gemcitabine-resistant RT-112 cell 
line. 
(a, b) Anti-proliferative effect of gemcitabine (a) and ASP5878 (b) in gemcitabine-
resistant RT-112 (GEM-R) and parental RT-112 cell lines. These cell lines were treated 
with gemcitabine and ASP5878 for 5 days [control: 0.1% DMSO (ASP5878), water 
(gemcitabine)]. Values are expressed as the mean ± SE from three separate experiments. 
(c) Gemcitabine-resistant RT-112 cell line was incubated for 2 h with each concentration 
of ASP5878 or 0.01% DMSO. Phosphorylated ERK (p-ERK), ERK and actin were 
detected by immunoblotting. (d) RT-112 and gemcitabine-resistant RT-112 cell lines were 
incubated for 48 h with each concentration of ASP5878 or 0.01% DMSO. c-MYC and 
actin were detected by immunoblotting.  
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Fig. 2-5. ASP5878 treatment leads to tumor regression in UM-UC-14, RT-112 and 
gemcitabine-resistant RT-112 subcutaneous xenograft models.  
(a) ASP5878 was administered by oral gavage once daily to nude mice bearing UM-UC-
14 tumors (n=10). (b) Tumor samples were collected from UM-UC-14 tumor-bearing 
mice at various time points (0.5, 1, 2, 4, 6, 12, 18 and 24 h) after single dose of ASP5878 
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and vehicle. Phosphorylated FGFR3 and total FGFR3 were measured by sandwich ELISA 
assay (n=3). (c) ASP5878 was administered by oral gavage once daily to nude mice 
bearing RT-112 tumors (n=5). (d) ASP5878 or gemcitabine was administered by oral 
gavage once-daily or intravenous injection twice-weekly to nude mice bearing 
gemcitabine-resistant RT-112 tumors (n=5). (e) Body weight of once-daily oral 
administration of ASP5878 for 14 days in nude mice bearing RT-112 cells (n=5). Each 
point represents the mean ± SE. Statistical analysis for antitumor tests was performed the 
values on the final day of each experiment (***P < 0.001, Dunnett’s multiple comparison 
test).  
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General Discussion 
The medical treatment techniques for cancers are largely divided in the following three 
categories: surgery, chemotherapy (anticancer agent), and radiotherapy. The checkpoint 
inhibitor has recently demonstrated effectiveness against some cancers, however the use 
has been limited. Surgery and radiotherapy are treatment only for local tumors, and 
patient’s HRQOL is markedly decreased such as depression of sexual function, urinary 
disorder and urinary tract diversion by surgery approach. On the other hand, anticancer 
agent may treat widespread deposits of tumor throughout the body, therefore, anticancer 
agents are remarkably helpful treatment for metastatic cancer. In this study, I focused 
attention on the anti-urological cancer agents by inhibition of tumor cell growth and 
proliferation in resistant status against existing treatments. 
In the first chapter, I described about the importance of the AKR1C3 function in 
androgen metabolism pathway produced in PCa. The production of androgen occurs not 
only in the testes, involving the conversion of AD to T by AKR1C3 [94], but also in the 
prostate by adrenal-derived DHEA [95]. Indeed, although surgical or medical castration 
with LH-RH agonists or antagonists reduce serum T levels by 90–97 %, the total androgen 
pool in the circulation and intraprostatic levels of DHT are only reduced by approximately 
60 % [40, 43]. AKR1C3 is one of the important enzymes in adrenal and de novo 
intratumoral steroidal biosynthesis, that is, AKR1C3 is involved in the conversion steps 
of DHEA to androstenediol and androstanedione to DHT, in addition to conversion of AD 
to T in PCa [96]. AA also inhibits androgen synthesis by the adrenal gland. AA targets 
CYP17α-hydroxylase/CYP17, 20-lyase, an enzyme that converts pregnenolone and 
progesterone into DHEA and AD via 2 subsequent reactions [97]. Both DHEA and AD 
are eventually transformed into T and DHT, the most potent androgen. However, 
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inhibition of CYP17α-hydroxylase also decreases serum cortisol levels, leading to a 
subsequent rise in adrenocorticotropic hormone and mineralocorticoids upstream of 
CYP17α-hydroxylase. To suppress potential side effects related to this mineralocorticoid 
rise, AA requires concomitant use of steroids such as prednisone. Furthermore, although 
it is initially effective, most patients receiving AA will progress in their disease by 15 
months of treatment [14]. Determining the mechanisms of resistance to first therapies has 
been being investigated and several adaptive pathways have been uncovered. One of the 
resistance mechanisms may be partially due to the presence of AR splice variants and 
mutation of the AR. Clinically, detection of AR-V7 in prostate cancer patients may 
indicate AA resistance [98], and the progesterone-activated T878A AR mutant is 
associated with resistance to AA [99]. In addition to such AR modification, increased 
expression of steroidogenic enzymes is another likely contributor to both PCa progression 
and AA resistance by increasing androgen levels and inducing AR activation [100, 101]. 
In AA or enzalutamide-resistant PCa cells, AKR1C3 is overexpressed and the levels of 
intracrine androgens are elevated. In addition, AKR1C3 activation increases intracrine 
androgen synthesis and enhances AR signaling via activating AR transcriptional activity. 
Treatment of AA or enzalutamide-resistant cells with AKR1C3 inhibitor, overcomes 
resistance and enhances AA therapy both in vitro and in vivo by reducing the levels of 
intracrine androgens and diminishing AR transcriptional activity [102, 103]. Then, 
AKR1C3 activation contributes to CRPC drug resistance in patients treated with both AA 
and enzalutamide, and it has been suggested as a biomarker for assessing prostate cancer 
progression [102, 104]. Increased expression of AKR1C3 is associated with PCa 
progression and aggressiveness. Moreover, it is not detectable in normal prostatic 
epithelium, however it is highly elevated in metastasized PCa. AKR1C3 may also act as 
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an AR selective coactivator that promotes tumor growth, and this coactivator function 
could be blocked with small molecule enzyme competitive inhibitors [59]. In the first 
chapter, I demonstrated that ASP9521 is a potent, orally bioavailable inhibitor of 
AKR1C3-mediated conversion of AD into T, both in vitro and in vivo in CWR22R 
xenografted castrate mice. ASP9521 also inhibited AD-dependent PSA production and 
proliferation in LNCaP-AKR1C3 cells. AKR1C2, closely related isoforms of AKR1C3, 
is involved in DHT metabolism, and inhibition of this isoform may lead to the 
accumulation of DHT in the prostate and thereby induce the development or progression 
of PCa. Therefore, AKR1C3 inhibitors without any inhibitory activity against AKR1C2 
is desirable for the treatment of PCa, and ASP9521 showed high selectivity to AKC1C3 
against AKR1C2. Furthermore, expression of AKR1C3 in tumor tissue was found to be a 
prerequisite for intratumoral accumulation of ASP9521. These results provided the 
rationale for ASP9521 in the treatment of mCRPC by inhibition of androgen synthesis 
necessary for PCa growth and proliferation. In addition, for cancer resistance, 
combination of ASP9521 with AA or enzalutamide is expected to be more effective. In 
ASP9521 phase I/II study, since none of the patients had received prior treatment with 
AA, it is hypothesized that AKR1C3 expression was insufficient to exert significant 
effects of ASP9521 in these patients. It is suggested that the importance of patient 
selection with the expression level of AKR1C3 and the concomitant use of a 5α-reductase 
inhibitor to completely block DHT production should be considered to have significant 
effect of ASP9521 in clinical study. 
In the second chapter, I described the FGFR3 inhibition mechanism in FGFR3-mutant 
cells by demonstrating the preclinical profile of ASP5878, which is a selective FGFR 
inhibitor targeting FGFR3-fusion or -mutation positive urothelial bladder cancer. Among 
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several large sequencing studies in urothelial bladder cancer which include 
NMIBC/MIBC and metastatic/nonmetastatic disease, 35–55 % of tumors had a mutation, 
translocation, or amplification of PIK3CA, EGFR, ERBB2, ERBB3, or FGFR3 [69, 105-
107]. Genomic alterations of FGFR3 have been identified in heterogeneous subsets of 
such urothelial bladder cancer patients. In 23 urothelial cancer cell lines, ASP5878 
inhibited the proliferation of RT-112 and RT4 harboring FGFR3-TACC3, SW 780 
harboring FGFR3-BAIAP2L1, UM-UC-14 harboring FGFR3_S249C and JMSU-1 
harboring FGFR1 overexpression (Fig. 2-1). Aside from FGFR3 gene alternations, 
JMSU-1 cell line harboring FGFR1 overexpression has been demonstrated to have 
FGFR1-dependent cell growth activity by using FGFR1 siRNA [76]. These findings 
suggest that FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR3_S249C mutations and FGFR1 
overexpression may be predictors of the sensitivity to ASP5878 in urothelial bladder 
cancer. Over the past 20 years, the standard therapy of MIBC or metastatic bladder cancer 
has been the combination of chemotherapeutic agents (GC and MVAC), however, their 
therapeutic effects have been generally unsatisfactory. One of the reasons is resistance to 
these chemotherapeutic agents, and induction of MDR1 overexpression or the alterations 
in the apoptotic machinery including overexpression of c-MYC, the resistance factors. I 
established adriamycin-resistant UM-UC-14 cell line harboring MDR1 overexpression 
and gemcitabine-resistant RT-112 cell line harboring c-MYC up-regulation by stepwise 
increasing concentrations of adriamycin, or gemcitabine. ASP5878 inhibited the 
proliferation of these resistant cell lines with similar potency to their parent cell lines. 
ASP5878 also inhibited ERK phosphorylation and induced c-MYC down-regulation in 
urothelial cancer cell line harboring FGFR3 gene alternation independent on gemcitabine 
resistant status. It is suggested that c-MYC expression may be regulated by the 
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FGFR/ERK signaling pathway in this study. ASP5878 also dose-dependently inhibited 
the tumor growth in gemcitabine-resistant RT-112 subcutaneous xenograft mouse model. 
In the second chapter, ASP5878, a selective FGFR inhibitor, showed potent anti-
proliferative and antitumor activity in urothelial bladder cancer cell lines harboring 
FGFR3-TACC3, FGFR3-BAIAP2L1 or FGFR3 point mutation and their tumor 
xenografted models. ASP5878 also inhibited the proliferation of adriamycin-resistant 
UM-UC-14 and gemcitabine-resistant RT-112 cell lines. These findings suggest that 
ASP5878 has therapeutic potential against urothelial bladder cancers harboring FGFR3-
TACC3, FGFR3-BAIAP2L1 or FGFR3 point mutation even after the acquisition of 
gemcitabine- or adriamycin-resistance. 
While great strides have been recently made in anticancer drug treatment, there remain 
considerable UMN from cancers that still cannot be effectively treated even today. My 
studies showed that the discovery and the development of anti-cancer drug for resistant 
status against existing treatments are possible based on their diverse physiological 
responses. AKR1C3 inhibitor for PCa and FGFR3 inhibitor for urothelial cancer 
harboring FGFR3 fusion or FGFR3 point mutation could lead to a novel and effective 
therapeutic approach for such urological cancer. 
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